Currently, immunotherapy clinical trials integrating the assessment of LB biomarkers in lung cancer and melanoma, such as EV-PD-L1 and miRNAs in NSCLC (NCT04427475) and EV-PD-L1 in melanoma (NCT05744076) (https://clinicaltrials.gov, accessed on 20 June 2024), are ongoing [174]. This evidence concerns the gene CD274 and melanoma.